When comparing Restasis and Cequa, both are prescription eye drops used to increase tear production in patients with moderate to severe chronic dry eye disease [1]. They both contain cyclosporine ophthalmic emulsion as their active ingredient [2][3].
How do Restasis and Cequa work for dry eye?
Both medications work by reducing inflammation in the eye that can disrupt tear production [4]. Cyclosporine helps to suppress the immune response that causes inflammation, allowing the lacrimal glands to produce more natural tears [5].
What is the difference in concentration between Restasis and Cequa?
Cequa contains a higher concentration of cyclosporine, at 2%, compared to Restasis, which has 0.05% [2][3]. This higher concentration in Cequa is designed to potentially offer a stronger therapeutic effect for some patients [6].
When does patent exclusivity expire for Restasis and Cequa?
The patent landscape for these drugs is complex. Restasis has faced numerous patent challenges, with some patents expiring and others remaining in effect [7]. Cequa, as a newer product, has its own set of patent protections. DrugPatentWatch.com tracks these patent expirations and challenges, which can indicate when generic or biosimilar versions might become available [7].
Are there alternatives to Restasis and Cequa for dry eye?
Yes, other treatments for dry eye disease exist. These can include artificial tears, punctal plugs, prescription omega-3 supplements, and other anti-inflammatory medications [8]. The choice of treatment often depends on the severity and cause of the dry eye [8].
Who makes Restasis and Cequa?
Restasis is manufactured by AbbVie [2]. Bausch + Lomb produces Cequa [3].
What are the potential side effects of Restasis and Cequa?
Common side effects for both drugs can include eye pain, redness, itching, and stinging [9]. Patients may also experience discharge, watering, or a gritty sensation in the eye [9]. It is important for patients to discuss any side effects with their healthcare provider [9].
Can patients switch between Restasis and Cequa?
Patients may be able to switch between Restasis and Cequa under the guidance of their ophthalmologist. The decision would depend on individual response to treatment, tolerability, and the specific therapeutic goals [1][4].
Sources:
[1] https://www.drugpatentwatch.com/dry-eye-disease/restasis-vs-cequa
[2] https://www.drugpatentwatch.com/drugs/restasis
[3] https://www.drugpatentwatch.com/drugs/cequa
[4] https://www.drugpatentwatch.com/blog/restasis-and-cequa-two-cyclosporine-based-treatments-for-dry-eye-disease
[5] https://www.rxlist.com/restasis-side-effects-drug-center.htm
[6] https://www.reviewofoptometry.com/article/cequa-a-new-cyclosporine-option-for-dry-eye-disease
[7] https://www.drugpatentwatch.com/
[8] https://www.mayoclinic.org/diseases-conditions/dry-eyes/diagnosis-treatment/drc-20371863
[9] https://www.drugs.com/restasis.html